Tuesday, March 23, 2021 : Issue #1117 |
|
Letter from the Editor
 When a relative is diagnosed with diabetes, your first inclination is to throw everything at the disease and then see what works best. That especially is the case if they start insulin on day 1. It started with a long acting insulin, an SGLT-2, and a GLP-1. This worked well till meal time insulin was needed. Then when a C-peptide test was done and type 1 was diagnosed, the Endo said no more Trulicity or Farxiga, which didn’t make sense. The reason was given that those products were not indicated for type 1 patients.
It could be this is changing; our intern, George McDowell, from LECOM, has a new study on the use of GLP-1 agonists for type 1 patients.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
